The Chinese State Drug Administration has not approved the use of nucleoside antivirals in pregnant women. However, the results of a set of clinical studies collected from 1989 to 2008 showed that there was no difference in the incidence of neonatal teratology between mothers who used these drugs during pregnancy and those who did not, whether lamivudine, telbivudine, or tenofovir, and whether they were applied during the first or second trimester of pregnancy. (The general neonatal teratogenicity rate in the United States is 2,72%, and the neonatal teratogenicity rate with nucleoside antivirals is 1,5-2,9%.) Therefore, the choice of whether to use nucleoside antivirals during pregnancy should be made by the patient after full communication between the doctor and the patient, and it is best to sign an informed consent form. HBV-DNA>107 (the earlier the better, the better, preferably before pregnancy, and then after the HBV-DNA turns negative, continue to use until the child is born) HBV-DNA>104 ___ HBV-DNA>107 Depending on the number of viruses, choose between early, middle (after 4 months) and late pregnancy (after 7 months). The drugs available: lamivudine, telbivudine, tenofovir Note: 1. If the hepatitis B virus is attached to the egg, it can still be transmitted through the egg, although it is rare. 2.